Gilead Sciences, the maker of one of the costliest drugs in the world, announced on Monday that it had struck agreements with seven Indian generic-drug makers to sell lower-cost versions of the medicine—a $1,000-a-pill hepatitis C treatment—in poorer countries.
Maker of hepatitis C drug strikes deal on generics for poor countries
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.